Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Corrigendum: Identification and Characterisation of a pH-stable GFP.

Roberts TM, Rudolf F, Meyer A, Pellaux R, Whitehead E, Panke S, Held M.

Sci Rep. 2018 May 17;8:46976. doi: 10.1038/srep46976.

2.

Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer.

Bergholz JS, Roberts TM, Zhao JJ.

J Clin Oncol. 2018 May 1;36(13):1339-1342. doi: 10.1200/JCO.2017.77.0891. Epub 2018 Mar 8. No abstract available.

PMID:
29517943
3.

Sequence-based prediction of permissive stretches for internal protein tagging and knockdown.

Oesterle S, Roberts TM, Widmer LA, Mustafa H, Panke S, Billerbeck S.

BMC Biol. 2017 Oct 30;15(1):100. doi: 10.1186/s12915-017-0440-0.

4.

Efficient engineering of chromosomal ribosome binding site libraries in mismatch repair proficient Escherichia coli.

Oesterle S, Gerngross D, Schmitt S, Roberts TM, Panke S.

Sci Rep. 2017 Sep 26;7(1):12327. doi: 10.1038/s41598-017-12395-3.

5.

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.

Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H.

Oncogene. 2018 Jan 18;37(3):341-351. doi: 10.1038/onc.2017.326. Epub 2017 Sep 25.

6.

CDK4/6 inhibition triggers anti-tumour immunity.

Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ.

Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.

7.

A small spacecraft for multipoint measurement of ionospheric plasma.

Roberts TM, Lynch KA, Clayton RE, Weiss J, Hampton DL.

Rev Sci Instrum. 2017 Jul;88(7):073507. doi: 10.1063/1.4992022.

PMID:
28764511
8.

CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.

Zhang J, Gao X, Schmit F, Adelmant G, Eck MJ, Marto JA, Zhao JJ, Roberts TM.

Cell Rep. 2017 Jul 18;20(3):549-557. doi: 10.1016/j.celrep.2017.06.054.

9.

PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.

Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, Zhao JJ.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7095-7100. doi: 10.1073/pnas.1704706114. Epub 2017 Jun 19.

10.

The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.

Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, Gao H, Yang G, Williams JA, Suski JM, Keibler MA, Sicinska E, Gerdemann U, Haining WN, Roberts TM, Polyak K, Gygi SP, Dyson NJ, Sicinski P.

Nature. 2017 Jun 15;546(7658):426-430. doi: 10.1038/nature22797. Epub 2017 Jun 7.

11.

Epigenetic regulation of RTK signaling.

Spangle JM, Roberts TM.

J Mol Med (Berl). 2017 Aug;95(8):791-798. doi: 10.1007/s00109-017-1546-0. Epub 2017 Jun 6. Review.

12.

The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.

Spangle JM, Roberts TM, Zhao JJ.

Biochim Biophys Acta. 2017 Aug;1868(1):123-131. doi: 10.1016/j.bbcan.2017.03.002. Epub 2017 Mar 14. Review.

13.

Synthetic Biology for Cell-Free Biosynthesis: Fundamentals of Designing Novel In Vitro Multi-Enzyme Reaction Networks.

Morgado G, Gerngross D, Roberts TM, Panke S.

Adv Biochem Eng Biotechnol. 2018;162:117-146. doi: 10.1007/10_2016_13. Review.

PMID:
27757475
14.

Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.

Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM.

Elife. 2016 Oct 4;5. pii: e17635. doi: 10.7554/eLife.17635.

15.

NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.

Yuzugullu H, Von T, Thorpe LM, Walker SR, Roberts TM, Frank DA, Zhao JJ.

Cell Discov. 2016 Sep 20;2:16030. doi: 10.1038/celldisc.2016.30. eCollection 2016.

16.

Exploiting racemases.

Femmer C, Bechtold M, Roberts TM, Panke S.

Appl Microbiol Biotechnol. 2016 Sep;100(17):7423-36. doi: 10.1007/s00253-016-7729-8. Epub 2016 Jul 22. Review.

PMID:
27444433
17.

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.

Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.

Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.

18.

Tyrosine receptor kinase B is a drug target in astrocytomas.

Ni J, Xie S, Ramkissoon SH, Luu V, Sun Y, Bandopadhayay P, Beroukhim R, Roberts TM, Stiles CD, Segal RA, Ligon KL, Hahn WC, Zhao JJ.

Neuro Oncol. 2017 Jan;19(1):22-30. doi: 10.1093/neuonc/now139. Epub 2016 Jul 10.

19.

Identification and Characterisation of a pH-stable GFP.

Roberts TM, Rudolf F, Meyer A, Pellaux R, Whitehead E, Panke S, Held M.

Sci Rep. 2016 Jun 21;6:28166. doi: 10.1038/srep28166. Erratum in: Sci Rep. 2018 May 17;8:46976.

20.

PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.

Spangle JM, Dreijerink KM, Groner AC, Cheng H, Ohlson CE, Reyes J, Lin CY, Bradner J, Zhao JJ, Roberts TM, Brown M.

Cell Rep. 2016 Jun 21;15(12):2692-704. doi: 10.1016/j.celrep.2016.05.046. Epub 2016 Jun 9.

21.

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.

Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ.

Nat Med. 2016 Jul;22(7):723-6. doi: 10.1038/nm.4120. Epub 2016 Jun 6.

22.

Delivery strategies and potential targets for siRNA in major cancer types.

Lee SJ, Kim MJ, Kwon IC, Roberts TM.

Adv Drug Deliv Rev. 2016 Sep 1;104:2-15. doi: 10.1016/j.addr.2016.05.010. Epub 2016 May 31. Review.

23.

Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.

Rouleau C, Pores Fernando AT, Hwang JH, Faure N, Jiang T, White EA, Roberts TM, Schaffhausen BS.

J Virol. 2016 Jul 27;90(16):7032-7045. doi: 10.1128/JVI.00417-16. Print 2016 Aug 15.

24.

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.

Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H.

Oncotarget. 2016 Mar 15;7(11):13153-66. doi: 10.18632/oncotarget.7549.

25.

Corrigendum: Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis.

Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ.

Nature. 2016 May 12;533(7602):278. doi: 10.1038/nature16543. Epub 2016 Jan 27. No abstract available.

PMID:
26814969
26.

PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.

Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ.

Oncogene. 2016 Jun 9;35(23):2961-70. doi: 10.1038/onc.2015.377. Epub 2015 Dec 7.

27.

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.

Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ.

Oncogene. 2016 Jul 7;35(27):3607-12. doi: 10.1038/onc.2015.406. Epub 2015 Oct 26.

28.

A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.

Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ.

Nat Commun. 2015 Oct 7;6:8501. doi: 10.1038/ncomms9501.

29.

Imaging free-falling particles for multipoint measurement of plasma fluctuations.

Roberts TM, Mauel ME, Abler MC, Makansi BK.

Rev Sci Instrum. 2015 Aug;86(8):083510. doi: 10.1063/1.4929407.

PMID:
26329195
30.

Correction for Hwang et al., Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation.

Hwang JH, Pores Fernando AT, Faure N, Andrabi S, Adelmant G, Hahn WC, Marto JA, Schaffhausen BS, Roberts TM.

J Virol. 2015 Jul;89(13):6971. doi: 10.1128/JVI.00952-15. No abstract available.

31.

Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens.

White EA, Kramer RE, Hwang JH, Pores Fernando AT, Naetar N, Hahn WC, Roberts TM, Schaffhausen BS, Livingston DM, Howley PM.

J Virol. 2015 Mar;89(5):2857-65. doi: 10.1128/JVI.03282-14. Epub 2014 Dec 24.

32.

The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation.

Csibi A, Lee G, Yoon SO, Tong H, Ilter D, Elia I, Fendt SM, Roberts TM, Blenis J.

Curr Biol. 2014 Oct 6;24(19):2274-80. doi: 10.1016/j.cub.2014.08.007. Epub 2014 Sep 11.

33.

Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation.

Hwang JH, Pores Fernando AT, Faure N, Andrabi S, Adelmant G, Hahn WC, Marto JA, Schaffhausen BS, Roberts TM.

J Virol. 2014 Oct;88(20):12055-64. doi: 10.1128/JVI.01399-14. Epub 2014 Aug 13. Erratum in: J Virol. 2015 Jul;89(13):6971. Adelmant, Guillaume and Marto, Jarrod A [Added].

34.

Polyoma small T antigen triggers cell death via mitotic catastrophe.

Pores Fernando AT, Andrabi S, Cizmecioglu O, Zhu C, Livingston DM, Higgins JM, Schaffhausen BS, Roberts TM.

Oncogene. 2015 May 7;34(19):2483-92. doi: 10.1038/onc.2014.192. Epub 2014 Jul 7.

35.

The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.

Utermark T, Schmit F, Lee SH, Gao X, Schaffhausen BS, Roberts TM.

J Virol. 2014 Sep;88(18):10673-9. doi: 10.1128/JVI.01409-14. Epub 2014 Jul 2.

36.

KRAS and YAP1 converge to regulate EMT and tumor survival.

Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC.

Cell. 2014 Jul 3;158(1):171-84. doi: 10.1016/j.cell.2014.06.004. Epub 2014 Jun 19.

37.

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6395-400. doi: 10.1073/pnas.1323004111. Epub 2014 Apr 15.

38.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ.

J Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.

39.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P.

Cancer Discov. 2013 Sep;3(9):1030-43. doi: 10.1158/2159-8290.CD-13-0142. Epub 2013 Jul 10.

40.

Spatial trends and factors affecting mercury bioaccumulation in freshwater fishes of Washington State, USA.

Mathieu C, Furl CV, Roberts TM, Friese M.

Arch Environ Contam Toxicol. 2013 Jul;65(1):122-31. doi: 10.1007/s00244-013-9882-8. Epub 2013 Feb 23. Erratum in: Arch Environ Contam Toxicol. 2013 Jul;65(1):171. Mattieu, Callie A [corrected to Mathieu, Callie].

PMID:
23435684
41.

Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM.

Cancer Discov. 2013 Jan;3(1):44-51. doi: 10.1158/2159-8290.CD-12-0262. Epub 2012 Dec 20.

42.

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM.

PLoS One. 2012;7(8):e44146. doi: 10.1371/journal.pone.0044146. Epub 2012 Aug 31.

43.

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.

Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, Ramos AH, Ross MG, Russ C, Shefler E, Sivachenko A, Sogoloff B, Stojanov P, Tamayo P, Mesirov JP, Amani V, Teider N, Sengupta S, Francois JP, Northcott PA, Taylor MD, Yu F, Crabtree GR, Kautzman AG, Gabriel SB, Getz G, Jäger N, Jones DT, Lichter P, Pfister SM, Roberts TM, Meyerson M, Pomeroy SL, Cho YJ.

Nature. 2012 Aug 2;488(7409):106-10. doi: 10.1038/nature11329.

44.

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ.

Genes Dev. 2012 Jul 15;26(14):1573-86. doi: 10.1101/gad.191973.112.

45.

Role of major sperm protein (MSP) in the protrusion and retraction of Ascaris sperm.

Roberts TM, Stewart M.

Int Rev Cell Mol Biol. 2012;297:265-93. doi: 10.1016/B978-0-12-394308-8.00007-8. Review.

PMID:
22608562
46.

Reconstitution of amoeboid motility in vitro identifies a motor-independent mechanism for cell body retraction.

Shimabukuro K, Noda N, Stewart M, Roberts TM.

Curr Biol. 2011 Oct 25;21(20):1727-31. doi: 10.1016/j.cub.2011.08.047. Epub 2011 Oct 13.

47.

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.

Ilic N, Utermark T, Widlund HR, Roberts TM.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E699-708. doi: 10.1073/pnas.1108237108. Epub 2011 Aug 29.

48.

Comparisons between murine polyomavirus and Simian virus 40 show significant differences in small T antigen function.

Andrabi S, Hwang JH, Choe JK, Roberts TM, Schaffhausen BS.

J Virol. 2011 Oct;85(20):10649-58. doi: 10.1128/JVI.05034-11. Epub 2011 Aug 10.

49.

Targeting PI3K signaling as a therapeutic approach for colorectal cancer.

Zhang J, Roberts TM, Shivdasani RA.

Gastroenterology. 2011 Jul;141(1):50-61. doi: 10.1053/j.gastro.2011.05.010. Review.

PMID:
21723986
50.

Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma.

Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM.

J Virol. 2011 Jun;85(11):5581-92. doi: 10.1128/JVI.02609-10. Epub 2011 Mar 16.

Supplemental Content

Loading ...
Support Center